506
Views
25
CrossRef citations to date
0
Altmetric
Drug Evaluations

Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain

, MD &
Pages 297-310 | Published online: 23 Dec 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Michael A Ueberall, Alice Eberhardt & Gerhard HH Mueller-Schwefe. (2016) Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice. International Journal of General Medicine 9, pages 39-51.
Read now
Sebastiano Mercadante & Antonello Giarratano. (2013) Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opinion on Investigational Drugs 22:1, pages 161-166.
Read now
Joseph Pergolizzi. (2011) Chronic pain – moving from symptom control to mechanism-based treatment. Current Medical Research and Opinion 27:10, pages 2079-2080.
Read now

Articles from other publishers (22)

Julia Rustemeier. (2017) Opioidtherapie: Aus der Schmerzspirale ausbrechen. Schmerzmedizin 33:5, pages 64-64.
Crossref
Tetsusuke Yoshimoto, Shiro Tomiyasu, Toshinari Saeki, Tomohiro Tamaki, Takahiro Hashizume, Masahiko Murakami & Motohiro Matoba. (2016) How Do Hospital Palliative Care Teams Use the WHO Guidelines to Manage Unrelieved Cancer Pain? A 1-Year, Multicenter Audit in Japan. American Journal of Hospice and Palliative Medicine® 34:1, pages 92-99.
Crossref
Sam H. Ahmedzai, Wojciech Leppert, Marcin Janecki, Artur Pakosz, Mark Lomax, Heike Duerr & Michael Hopp. (2014) Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Supportive Care in Cancer 23:3, pages 823-830.
Crossref
Sabine Hesselbarth, Oliver Löwenstein & Thomas Cegla. (2014) Effects of prolonged-release oxycodone/naloxone on pain control, bowel function and quality of life: A prospective observational study. Scandinavian Journal of Pain 5:2, pages 75-81.
Crossref
Claudia Trenkwalder, Heike Beneš, Ludger Grote, Diego García-Borreguero, Birgit Högl, Michael Hopp, Björn Bosse, Alexander Oksche, Karen Reimer, Juliane Winkelmann, Richard P Allen & Ralf Kohnen. (2013) Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. The Lancet Neurology 12:12, pages 1141-1150.
Crossref
Michael A. Überall. (2013) Chancen optimieren, Risiken minimieren. MMW - Fortschritte der Medizin 155:25, pages 63-71.
Crossref
Lara Dhingra, Elyse Shuk, Bella Grossman, Alessandra Strada, Emily Wald, Allison Portenoy, Helena Knotkova & Russell Portenoy. (2012) A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliative Medicine 27:5, pages 447-456.
Crossref
Joseph Pergolizzi, Cayetano Alegre, David Blake, Jaime Calvo Alén, Roberto Caporali, Hans‐Raimund Casser, Gerardo Correa‐Illanes, Pedro Fernandes, Eugenio Galilea, Richard Jany, Anthony Jones, Othmane Mejjad, Jadranka Morovic‐Vergles, Ángel Oteo Álvaro, Francisco J. Radrigán Araya, Maria Eugénia C. Simões & Generoso Uomo. (2011) Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol. Pain Practice 12:4, pages 290-306.
Crossref
Richard H. Rech, David J. Mokler & Shannon L. Briggs. (2012) Effects of Combined Opioids on Pain and Mood in Mammals. Pain Research and Treatment 2012, pages 1-11.
Crossref
Gálvez Rafael, Provencio Mariano, Sanz-Ortiz Jaime, Ribera Ma Victoria, Esteban Emilio, Collado Francisco, Vara Francisco, Díaz Pilar, Rocafort Javier, Cobo Manuel, Traseira Susana & Brosa Max. (2013) Análisis económico de oxicodona LP/ naloxona LP en el manejo del dolor intenso y el estreñimiento asociado al tratamiento con opioides en España. PharmacoEconomics Spanish Research Articles 9:1, pages 23-34.
Crossref
Sam H Ahmedzai, Friedemann Nauck, Gil Bar-Sela, Björn Bosse, Petra Leyendecker & Michael Hopp. (2011) A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine 26:1, pages 50-60.
Crossref
Nagi B. KumarNagi B. Kumar. 2012. Nutritional Management of Cancer Treatment Effects. Nutritional Management of Cancer Treatment Effects 221 244 .
Andreas Sandner-Kiesling. (2011) Re: Opioid-Induced Constipation: Challenges and Therapeutic Opportunities. American Journal of Gastroenterology 106:12, pages 2200.
Crossref
Sebastiano Mercadante. (2011) Emerging drugs for cancer-related pain. Supportive Care in Cancer 19:12, pages 1887-1893.
Crossref
Patricia PapaLeticia Turconi. (2011) Neostigmine for the Treatment of Gastrointestinal Atony: A Report of One Case. Journal of Palliative Medicine 14:11, pages 1270-1273.
Crossref
K. E. Clemens, I. Quednau & E. Klaschik. (2011) Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. International Journal of Clinical Practice 65:4, pages 472-478.
Crossref
Anne Estrup Olesen & Asbjørn Mohr Drewes. (2011) Validated tools for evaluating opioid-induced bowel dysfunction. Advances in Therapy 28:4, pages 279-294.
Crossref
J. Kerdraon, M. Eleouet, P. Coignard & L. Siproudhis. (2010) Constipation iatrogèneIatrogenic constipation. Pelvi-périnéologie 5:4, pages 261-266.
Crossref
. (2010) Current World Literature. Current Opinion in Anaesthesiology 23:5, pages 671-678.
Crossref
Peter Holzer. (2010) Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Current Opinion in Anaesthesiology 23:5, pages 616-622.
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:8, pages i-xiii.
Crossref
R. William Hipkin & Roland E. Dolle. 2010. 142 155 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.